Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients.

Transl Lung Cancer Res · 2022 · PMC8902085 · PMID 35280315

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The ctDNA-negative participants showed a trend for longer RFS (ctDNA+ vs. ctDNA−, 13.4 months vs.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.